Saturday 17 October 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow LIPO
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 4 | 3 | 4 | 3 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 12.56 | 5.96 |
Altman Z-Score |
— | — | — | 4.17 | 1.21 | (10.72) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (0.27) | (4.11) | 2.90 | (5.11) | (24.23) |
P/Operating CF |
(73.74) | (73.74) | (73.74) | (56.16) | (7.76) | (3.23) |
Beneish M-Score |
— | — | — | — | (4.28) | (3.83) |
P/B ratio |
0.00 | 0.00 | 0.00 | 2.78 | 1.80 | 1.67 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 2.78 | 1.80 | 1.67 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 5.90 | 2.45 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(9.13) | (9.13) | (9.13) | (4.46) | (0.84) | (0.33) |
EV/FCF |
(9.13) | (9.13) | (9.13) | (4.46) | (0.84) | (0.33) |
Quick Ratio |
0.66 | 3.25 | 5.03 | 4.44 | 8.63 | 3.01 |
Current Ratio |
0.72 | 3.37 | 5.31 | 4.92 | 8.90 | 3.47 |
Net Debt/EBITDA |
(1.38) | 8.41 | 0.86 | 1.88 | 0.69 | 0.43 |
Debt/Assets |
84.10% | 13.40% | 3.73% | 4.20% | 0.00% | 0.00% |
Debt/Equity |
(0.85) | 0.28 | 0.05 | 0.05 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 1.79 | 0.17 | 0.05 | 0.09 | 0.17 |
Operating CF/Net income |
0.63 | 0.46 | 0.53 | 0.70 | 0.68 | 0.79 |
Capex/Depreciation |
— | — | — | — | (8.47) | 0.00 |
Interest Coverage |
(12.37) | (7.11) | (281.74) | (269.76) | (439.44) | — |
| 0.00% | (35.80%) | (197.76%) | (85.18%) | (118.13%) | (198.12%) | |
| 0.00% | (11.49%) | (125.71%) | (65.24%) | (96.96%) | (160.49%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
132.05% | (8.26%) | (111.55%) | (54.44%) | (151.11%) | (267.85%) |
Average Days of Receivables |
44.08 | 26.19 | 0.00 | 225.30 | 26.22 | 57.64 |
Research and Development Expense of Revenue |
98.30% | 101.49% | 561.82% | 1,383.12% | 675.89% | 673.60% |
Selling, General and Administrative Expense of Revenue |
9.44% | 4.43% | 277.05% | 122.80% | 479.69% | 373.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 6.00% | 281.06% | 405.75% | 328.34% | 176.99% |
Graham Net Nets |
0.03 | 0.03 | 0.03 | 0.35 | 0.53 | 0.58 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(19.99%) | (19.99%) | (19.99%) | (19.99%) | (82.87%) | (154.75%) |
Free Cash Flow Yield |
(10.96%) | (10.96%) | (10.96%) | (14.09%) | (56.04%) | (124.05%) |
Revenue per Share |
0.12 | 1.44 | 0.61 | 0.36 | 0.60 | 0.51 |
Operating CF per Share |
(0.01) | (0.04) | (2.32) | (3.61) | (4.20) | (3.77) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 |
Free Cash Flow per Share |
(0.01) | (0.04) | (2.32) | (3.61) | (4.22) | (3.77) |
Cash per Share |
0.00 | 0.91 | 4.02 | 10.09 | 4.39 | 2.08 |
Shareholders Equity per Share |
(0.02) | 0.70 | 3.34 | 9.21 | 4.19 | 1.83 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.02) | 0.70 | 3.34 | 9.21 | 4.19 | 1.83 |
Free Cash Flow |
(0.04) | (0.03) | (0.99) | (1.83) | (3.16) | (3.95) |
Working Capital |
(0.05) | 0.49 | 1.47 | 4.62 | 3.04 | 1.86 |
Capital Expenditures |
— | — | — | — | (0.01) | — |
Net Current Asset Value |
(0.12) | 0.21 | 1.22 | 4.52 | 3.00 | 1.86 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.13 | 0.29 |
Cash ROIC |
(507.79%) | (2.39%) | (30.79%) | (18.23%) | (49.15%) | (96.26%) |
Accounts Receivable Turnover |
0.00 | 12.58 | 0.00 | 2.02 | 6.16 | 9.17 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.08 | — | 0.09 | 0.07 | 0.06 |
Average Payables |
— | 0.04 | 0.04 | 0.22 | 0.26 | 0.26 |
Average Assets |
— | 0.54 | 1.48 | 3.98 | 4.76 | 3.13 |
Average Common Equity |
— | 0.17 | 0.94 | 3.05 | 3.91 | 2.53 |
Columns are period end dates